Researchers at Baylor College of Medicine have discovered a natural mechanism that clears existing amyloid plaques in the brains of mouse models of Alzheimer’s disease and preserves cognitive function ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

The Simpsons recently blew up the internet with its 36th season finale flash-forward, which led many (too many!) people to mistakenly believe that the Fox comedy had killed off beloved matriarch Marge ...

If we can fully map the structure of our brains, will we be able to understand how they work? That is the goal of researchers attempting to build a wiring diagram, or connectome, of our neural ...

When the iPhone 14 Pro models were announced in 2022, Apple surprised many with its innovative integration of software functions with the pill-shaped cutout at the top of the screen. Apple calls this ...

Microsoft’s Copilot generative AI is popping up on the web, in mobile apps, in the Edge browser, and especially in Windows. But just what exactly is it? Here’s everything you need to know. I've been ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...